1-4 of 4
Randeep Sangha, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies

Michael J. Weickert, PhD, John Dillberger, DVM, PhD, Caren Brown, Francis Phaneuf, John R. Mackey, MD, Randeep Sangha, MD, Luc G. Berthiaume, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-141910
Published: 2020
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018
Journal Articles

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag, Julio C. Chavez, MD, Umberto Vitolo, MD, Jason B. Kaplan, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Loretta Nastoupil, MD, Philippe A. Cassier, MD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Ranjana H. Advani, MD, Iris Isufi, MD, Thomas E Witzig, MD, Michael Petrarca, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1551.
https://doi.org/10.1182/blood.V130.Suppl_1.1551.1551
Published: 2017
Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD
Journal: Blood
Blood (2012) 120 (21): 56.
https://doi.org/10.1182/blood.V120.21.56.56
Published: 2012